On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
- Council to Discuss Medical Needs for Additional Indications for Antiemetics Ondansetron, Granisetron
May 27, 2020
- Japan’s First Humalog Biosimilar to Join NHI Price List on May 27
May 26, 2020
- Final Report from Govt’s All-Generation Social Security Council to Be Delayed until Year-End
May 26, 2020
- June Approval Likely for Entresto as It Clears Key Panel; HFpEF Use OK’ed Too
May 25, 2020
- Panel OKs Ofev for PF-ILD; Label Expansion for Xtandi/Erleada, Prevenar and More
May 25, 2020
- MSD’s 9-Valent HPV Vaccine Now in Line for June Approval; Eyes on Its Possible Inclusion in National Immunization Program
May 25, 2020
- PMDA Reviewing Safety Risks for Avastin, Memary
May 25, 2020
- AMED to Fund 4 Company-Led COVID-19 Vaccine Development Projects
May 25, 2020
- Avigan Not Yet Filed in Japan, but Govt Still Seeks Approval by Month-End: Kato
May 25, 2020
- Add MSD’s 9-Valent HPV Vaccine to National Immunization Program If Approved: Lawmakers
May 21, 2020
- Label Revisions Ordered for 15 Insulins, Erleada, Faslodex
May 20, 2020
- MHLW Adds Veklury in Updated COVID-19 Treatment Guide
May 20, 2020
- LDP Lawmakers Call for Environment to Facilitate Vaccine Development
May 20, 2020
- Check Latest Info and Make Careful Decision on Veklury Use: PMDA Review Report
May 19, 2020
- MHLW Panel to Discuss HIF-PH Inhibitors from GSK, Mitsubishi Tanabe on May 29
May 19, 2020
- MHLW Panel to Discuss Orphan Status for 5 Cell and Gene Products
May 19, 2020
- Health Ministers of Japan, China, South Korea Commit to Support WHO on COVID-19, Timely Share Info
May 19, 2020
- Govt Won't Require Fujifilm-Sponsored Trial Data to Approve Avigan for COVID-19: Abe
May 18, 2020
- Novartis’ Tabrecta, Enerzair Up for MHLW Panel Review on May 28
May 15, 2020
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…